ReviewInternational journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists2026
Vulvar Squamous Cell Carcinoma: Scientific Progress and Impacts to Pathology Practice.
Review in International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite vulvar cancer's rarity, meaningful advances have been made to improve the clinical care of affected patients-particularly with respect to vulvar squamous cell carcinoma (VSCC). These advances are reflected in changes to tumor classification, surgical strategies, early detection of precursors, and targeted therapeutic exploration. Refinements in histopathologic and molecular classification have enhanced diagnostic precision, enabling more accurate prognostication and facilitating personalized therapeutic decision-making, particularly tailored surgical strategies that can be explored through clinical trials-to improve patient outcomes while reducing patient morbidity. Increased awareness of VSCC precursors have also opened avenues for earlier intervention. This review highlights the key changes in the evolution of VSCC care, with particular emphasis on the expanding responsibilities of pathologists in tumor subtyping [by human papillomavirus (HPV) and p53 status], biomarker-based prognostication, margin evaluation, recognition of precursors and alignment of precursor terminology (particularly HPV independent p53 wild-type lesions). By highlighting both progress and limitations, this review aims to inform future strategies that will further optimize patient outcomes and advance the standard of care in VSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.